Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

NCT02105701 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Infection

Interventions

DRUG: Grazoprevir + Elbasvir
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC